Integrating oncolytic viruses in combination cancer immunotherapy von Bommareddy, Praveen K., Shettigar, Megha, Kaufman, Howard L.

Volltext

Oncolytic viruses: a new class of immunotherapy drugs von Kaufman, Howard L., Kohlhapp, Frederick J., Zloza, Andrew

Volltext

Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy von Kohlhapp, Frederick J, Kaufman, Howard L

Volltext

Can Biomarkers Guide Oncolytic Virus Immunotherapy? von Kaufman, Howard L

Volltext

Clinical landscape of oncolytic virus research in 2020 von Macedo, Nicholas, Miller, David M, Haq, Rizwan, Kaufman, Howard L

Volltext

Therapy with oncolytic viruses: progress and challenges von Shalhout, Sophia Z., Miller, David M., Emerick, Kevin S., Kaufman, Howard L.

Volltext

Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma von Bommareddy, Praveen K., Patel, Anand, Hossain, Saamia, Kaufman, Howard L.

Volltext

Advancing oncolytic virus therapy by understanding the biology von Kaufman, Howard L., Maciorowski, Dawid

Volltext

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial von Kaufman, Howard L, Prof, Russell, Jeffery, MD, Hamid, Omid, MD, Bhatia, Shailender, MD, Terheyden, Patrick, MD, D'Angelo, Sandra P, MD, Shih, Kent C, MD, Lebbé, Céleste, Prof, Linette, Gerald P, MD, Milella, Michele, MD, Brownell, Isaac, MD, Lewis, Karl D, MD, Lorch, Jochen H, MD, Chin, Kevin, MD, Mahnke, Lisa, MD, von Heydebreck, Anja, PhD, Cuillerot, Jean-Marie, MD, Nghiem, Paul, Prof

Volltext

Can Surgeons Expand the Role of Oncolytic Viruses for Cancer Treatment? An Editorial Comment on “Fighting Fire with Fire: Oncolytic Virotherapy in Thoracic Malignancies” von Kaufman, Howard L.

Volltext

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advance... von Chesney, Jason, Puzanov, Igor, Collichio, Frances, Singh, Parminder, Milhem, Mohammed M, Glaspy, John, Hamid, Omid, Ross, Merrick, Friedlander, Philip, Garbe, Claus, Logan, Theodore F, Hauschild, Axel, Lebbé, Celeste, Chen, Lisa, Kim, Jenny J, Gansert, Jennifer, Andtbacka, Robert H I, Kaufman, Howard L

Volltext

Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer von Mehnert, Janice M, Panda, Anshuman, Zhong, Hua, Hirshfield, Kim, Damare, Sherri, Lane, Katherine, Sokol, Levi, Stein, Mark N, Rodriguez-Rodriquez, Lorna, Kaufman, Howard L, Ali, Siraj, Ross, Jeffrey S, Pavlick, Dean C, Bhanot, Gyan, White, Eileen P, DiPaola, Robert S, Lovell, Ann, Cheng, Jonathan, Ganesan, Shridar

Volltext

Immunotherapy for Nonmelanoma Skin Cancer: Facts and Hopes von Shalhout, Sophia Z, Kaufman, Howard L, Emerick, Kevin S, Miller, David M

Volltext

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy von Rehman, Hasan, Silk, Ann W., Kane, Michael P., Kaufman, Howard L.

Volltext

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma von Andtbacka, Robert H I, Collichio, Frances, Harrington, Kevin J, Middleton, Mark R, Downey, Gerald, Ӧhrling, Katarina, Kaufman, Howard L

Volltext

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma von Puzanov, Igor, Milhem, Mohammed M, Minor, David, Hamid, Omid, Li, Ai, Chen, Lisa, Chastain, Michael, Gorski, Kevin S, Anderson, Abraham, Chou, Jeffrey, Kaufman, Howard L, Andtbacka, Robert H I

Volltext

Interleukin-2, Ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma von Hughes, Tasha, Klairmont, Matthew, Sharfman, William H., Kaufman, Howard L.

Volltext

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma von Gross, Neil D., Miller, David M., Khushalani, Nikhil I., Divi, Vasu, Ruiz, Emily S., Lipson, Evan J., Meier, Friedegund, Su, Yungpo B., Swiecicki, Paul L., Atlas, Jennifer, Geiger, Jessica L., Hauschild, Axel, Choe, Jennifer H., Hughes, Brett G.M., Schadendorf, Dirk, Patel, Vishal A., Homsi, Jade, Taube, Janis M., Lim, Annette M., Ferrarotto, Renata, Kaufman, Howard L., Seebach, Frank, Lowy, Israel, Yoo, Suk-Young, Mathias, Melissa, Fenech, Keilah, Han, Hyunsil, Fury, Matthew G., Rischin, Danny

Volltext

Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma von Kaufman, Howard L, Ruby, Carl E, Hughes, Tasha, Slingluff, Jr, Craig L

Volltext

Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma von Bommareddy, Praveen K., Zloza, Andrew, Rabkin, Samuel D., Kaufman, Howard L.

Volltext